Sphingolipid, ceramide has been reported to initiate Nlrp3 inflammasome formation and activation in different pathological conditions including insulin resistance, obesity, Alzheimer's disease, cystic fibrosis and acute lung injury [6, 7]. This evidence concerns the gene NLRP3 and Obesity.